downstream signaling pathways, including the RAS/RAF/MEK/ERK pathway. Mutant c-KIT has been implicated in the pathogenesis of several cancers.

Despite B-Raf specific inhibitors (such as vemurafenib), and compounds such as those disclosed in WO 2006/039718 and WO 2008/034008, there is a need for a Raf inhibitor active in inhibiting all isoforms of Raf proteins including A-Raf, B-Raf, C-Raf, and B-Raf V600E mutation. There is a further need for a Raf inhibitor that is active against tumor cells with upstream pathway activation by N-Ras mutations, K-Ras mutations, and cKit mutations. Furthermore, there remains a need to provide alternative Raf inhibitors for treatment of cancer. There also remains a need to provide alternative Raf inhibitors active in inhibiting A-Raf, B-Raf, C-Raf, and B-Raf V600E mutation for treatment of cancer. Accordingly, the present ~~invention~~ disclosure provides a Raf inhibitor which may be active in inhibiting all isoforms of Raf proteins. Also, the present ~~invention~~ disclosure provides a Raf inhibitor which may be active against tumor cells with upstream pathway activation by N-Ras mutations, K-Ras mutations, and cKit mutations. Additionally, the present ~~invention~~ disclosure provides an alternative inhibitor of Raf. Furthermore, the present ~~invention~~ disclosure provides an alternative inhibitor of Raf which may be useful for treating cancer. The present ~~invention~~ disclosure also provides an alternative inhibitor of Raf active in inhibiting A-Raf, B-Raf, C-Raf, and B-Raf V600E mutation. Still further, the present ~~invention~~ disclosure provides an alternative inhibitor of Raf active in inhibiting A-Raf, B-Raf, C-Raf, and B-Raf V600E mutation which may be useful for treating cancer.

In a first aspect, there is provided a compound which is 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea, or a pharmaceutically acceptable salt thereof.

In a second aspect, there is provided a pharmaceutical composition comprising a compound as defined above, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable carrier.

In a third aspect, there is provided a pharmaceutical composition comprising the compound or salt as defined above, and a pharmaceutically acceptable carrier, diluent, or excipient.

In a fourth aspect, there is provided a pharmaceutical composition comprising the compound or salt as defined above, and polyvinyl pyrrolidone vinyl acetate (PVP-VA).

In a fifth aspect, there is provided the compound or salt as defined above for use in therapy.

In the sixth aspect, there is provided the compound or salt as defined above for use in the treatment of cancer.

Figure 1 is a representative X-ray powder diffraction pattern for Example 1.

The present invention provides a compound which is 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea, or a pharmaceutically acceptable salt thereof.

As a particular embodiment, the present invention provides the compound which is 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea.